> Skip repeated content

What is the cost-effectiveness profile of TJA performed with bone cement that contains antibiotics?

Orthopedics Today—October 17, 2018

Thomas P. Sculco, MD, surgeon-in-chief emeritus at HSS, provides the counter-point for Orthopedic Today's cover story on antibiotic bone cement.

He writes that continued efforts to reduce periprosthetic infection (a catastrophic event) have made the need for antibiotic-impregnated cement in routine arthroplasty not cost effective and with possible serious downsides.

"It would require reduction of the current 1 percent infection rate to an impossible 0.04 percent for use of ABLC [antibiotic-loaded cement] to be cost neural," he explains.

Additionally, he describes how a major detrimental effect of using ABLC is the potential for resistant organisms. Studies have shown that there is a rapid mutation of bacteria when confronted with antibiotics which could lead to difficulty in eradicating infections due to these resistant organisms.

Read the full counter point at Healio.com.

 

 

Need Help Finding a Physician?

Call us toll-free at:
+1.877.606.1555

Media Contacts

212.606.1197
mediarelations@hss.edu

Social Media Contacts